{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:27:47Z","timestamp":1786980467494,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001412","name":"Council\u00a0of\u00a0Scientific and Industrial Research, India","doi-asserted-by":"publisher","award":["Pool No 8948A\/17"],"award-info":[{"award-number":["Pool No 8948A\/17"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007338","name":"All-India Institute of Medical Sciences","doi-asserted-by":"publisher","award":["Neurosciences Centre"],"award-info":[{"award-number":["Neurosciences Centre"]}],"id":[{"id":"10.13039\/501100007338","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Brain Tumor Pathol"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s10014-020-00385-9","type":"journal-article","created":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T07:02:21Z","timestamp":1604214141000},"page":"30-40","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["EZH2 inhibitory protein (EZHIP\/Cxorf67) expression correlates strongly with H3K27me3 loss in posterior fossa ependymomas and is mutually exclusive with H3K27M mutations"],"prefix":"10.1007","volume":"38","author":[{"given":"Aruna","family":"Nambirajan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agrima","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu","family":"Rajeshwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meher Tej","family":"Boorgula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Doddamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishali","family":"Suri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitra","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4948-3296","authenticated-orcid":false,"given":"Mehar Chand","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,1]]},"reference":[{"key":"385_CR1","first-page":"106","volume-title":"WHO classification of tumours of the central nervous system, revised","author":"DW Ellison","year":"2016","unstructured":"Ellison DW, McLendon R, Wiestler OD et al (2016) Ependymoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system, revised, 4th edn. IARC, Lyon, pp 106\u2013112","edition":"4"},{"key":"385_CR2","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/S0002-9440(10)64491-4","volume":"161","author":"S Dyer","year":"2002","unstructured":"Dyer S, Prebble E, Davison V et al (2002) Genomic imbalances in pediatric intracranial ependymomas define clinically relevant groups. Am J Pathol 161:2133\u20132141","journal-title":"Am J Pathol"},{"key":"385_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00401-016-1643-0","volume":"133","author":"KW Pajtler","year":"2017","unstructured":"Pajtler KW, Mack SC, Ramaswamy V et al (2017) The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathol 133:5\u201312","journal-title":"Acta Neuropathol"},{"key":"385_CR4","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1200\/JCO.2009.27.3359","volume":"28","author":"A Korshunov","year":"2010","unstructured":"Korshunov A, Witt H, Hielscher T et al (2010) Molecular staging of intracranial ependymoma in children and adults. J Clin Oncol 28:3182\u20133190","journal-title":"J Clin Oncol"},{"key":"385_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ccr.2011.07.007","volume":"20","author":"H Witt","year":"2011","unstructured":"Witt H, Mack SC, Ryzhova M et al (2011) Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 20:143\u2013157","journal-title":"Cancer Cell"},{"key":"385_CR6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00401-012-0941-4","volume":"123","author":"K Wani","year":"2012","unstructured":"Wani K, Armstrong TS, Vera-Bolanos E et al (2012) A prognostic gene expression signature in infratentorial ependymoma. Acta Neuropathol 123:727\u2013738","journal-title":"Acta Neuropathol"},{"key":"385_CR7","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nature13108","volume":"506","author":"SC Mack","year":"2014","unstructured":"Mack SC, Witt H, Piro RM, Gu L, Zuyderduyn S, St\u00fctz AM et al (2014) Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 506:445\u2013450","journal-title":"Nature"},{"key":"385_CR8","doi-asserted-by":"publisher","first-page":"366ra161","DOI":"10.1126\/scitranslmed.aah6904","volume":"8","author":"J Bayliss","year":"2016","unstructured":"Bayliss J, Mukherjee P, Lu C et al (2016) Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas. Sci Transl Med. 8:366ra161","journal-title":"Sci Transl Med."},{"key":"385_CR9","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ccell.2015.04.002","volume":"27","author":"KW Pajtler","year":"2015","unstructured":"Pajtler KW, Witt H, Sill M, Jones DT, Hovestadt V, Kratochwil F et al (2015) Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell 27:728\u2013743","journal-title":"Cancer Cell"},{"issue":"2","key":"385_CR10","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s00401-018-1877-0","volume":"136","author":"KW Pajtler","year":"2018","unstructured":"Pajtler KW, Wen J, Sill M et al (2018) Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. Acta Neuropathol 136(2):211\u2013226","journal-title":"Acta Neuropathol"},{"key":"385_CR11","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1200\/JCO.2015.65.7825","volume":"34","author":"V Ramaswamy","year":"2016","unstructured":"Ramaswamy V, Hielscher T, Mack SC et al (2016) Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular era: a retrospective multicohort analysis. J Clin Oncol 34:2468\u20132477","journal-title":"J Clin Oncol"},{"key":"385_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12832","author":"DN Louis","year":"2020","unstructured":"Louis DN, Wesseling P, Aldape K et al (2020) cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol. https:\/\/doi.org\/10.1111\/bpa.12832 (published online ahead of print, 2020 Apr 19)","journal-title":"Brain Pathol."},{"key":"385_CR13","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1002\/cncr.31995","volume":"125","author":"M Zapotocky","year":"2019","unstructured":"Zapotocky M, Beera K, Adamski J et al (2019) Survival and functional outcomes of molecularly defined childhood posterior fossa ependymoma: cure at a cost. Cancer 125:1867\u20131876","journal-title":"Cancer"},{"key":"385_CR14","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s10014-019-00350-1","volume":"36","author":"A Nambirajan","year":"2019","unstructured":"Nambirajan A, Malgulwar PB, Sharma A et al (2019) Clinicopathological evaluation of PD-L1 expression and cytotoxic T-lymphocyte infiltrates across intracranial molecular subgroups of ependymomas: are these tumors potential candidates for immune check-point blockade? Brain Tumor Pathol 36:152\u2013161","journal-title":"Brain Tumor Pathol"},{"key":"385_CR15","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.cell.2020.04.047","volume":"181","author":"KA Michealraj","year":"2020","unstructured":"Michealraj KA, Kumar SA, Kim LJY et al (2020) Metabolic regulation of the epigenome drives lethal infantile ependymoma. Cell 181:1329\u20131345","journal-title":"Cell"},{"key":"385_CR16","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1093\/neuonc\/noz058","volume":"21","author":"JM H\u00fcbner","year":"2019","unstructured":"H\u00fcbner JM, M\u00fcller T, Papageorgiou DN et al (2019) EZHIP\/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma. Neuro Oncol 21:878\u2013889","journal-title":"Neuro Oncol"},{"key":"385_CR17","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1038\/s41467-019-09981-6","volume":"10","author":"SU Jain","year":"2019","unstructured":"Jain SU, Do TJ, Lund PJ et al (2019) PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism. Nat Commun 10:2146","journal-title":"Nat Commun"},{"key":"385_CR18","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.molcel.2016.10.018","volume":"64","author":"M Beringer","year":"2016","unstructured":"Beringer M, Pisano P, Di Carlo V et al (2016) EPOP functionally links elongin and polycomb in pluripotent stem cells. Mol Cell 64:645\u2013658","journal-title":"Mol Cell"},{"key":"385_CR19","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00401-015-1478-0","volume":"130","author":"D Castel","year":"2015","unstructured":"Castel D, Philippe C, Calmon R et al (2015) Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol 130:815\u2013827","journal-title":"Acta Neuropathol"},{"key":"385_CR20","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00401-017-1752-4","volume":"134","author":"P Panwalkar","year":"2017","unstructured":"Panwalkar P, Clark J, Ramaswamy V, Hawes D, Yang F, Dunham C et al (2017) Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. Acta Neuropathol 134:705\u2013714","journal-title":"Acta Neuropathol"},{"key":"385_CR21","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s40478-018-0630-1","volume":"6","author":"K Fukuoka","year":"2018","unstructured":"Fukuoka K, Kanemura Y, Shofuda T et al (2018) Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors. Acta Neuropathol Commun 6:134","journal-title":"Acta Neuropathol Commun"},{"key":"385_CR22","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00381-020-04518-5","volume":"36","author":"B Tanr\u0131kulu","year":"2020","unstructured":"Tanr\u0131kulu B, Danyeli AE, \u00d6zek MM (2020) Is H3K27me3 status really a strong prognostic indicator for pediatric posterior fossa ependymomas? A single surgeon, single center experience. Childs Nerv Syst 36:941\u2013949","journal-title":"Childs Nerv Syst"},{"key":"385_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1477-5751-10-7","volume":"10","author":"DW Ellison","year":"2011","unstructured":"Ellison DW, Kocak M, Figarella-Branger D et al (2011) Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. J Negat Results Biomed 10:7","journal-title":"J Negat Results Biomed"},{"key":"385_CR24","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s11060-015-2047-z","volume":"127","author":"M Rajeshwari","year":"2016","unstructured":"Rajeshwari M, Sharma MC, Kakkar A et al (2016) Evaluation of chromosome 1q gain in intracranial ependymomas. J Neurooncol 127:271\u2013278","journal-title":"J Neurooncol"},{"key":"385_CR25","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/neup.12594","volume":"39","author":"P Jha","year":"2019","unstructured":"Jha P, Manjunath N, Singh J et al (2019) Analysis of PD-L1 expression and T cell infiltration in different molecular subgroups of diffuse midline gliomas. Neuropathology 39:413\u2013424","journal-title":"Neuropathology"},{"key":"385_CR26","doi-asserted-by":"publisher","first-page":"e0178351","DOI":"10.1371\/journal.pone.0178351","volume":"12","author":"F Andreiuolo","year":"2017","unstructured":"Andreiuolo F, Le Teuff G, Bayar MA et al (2017) Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: a new model for risk stratification. PLoS ONE 12:e0178351","journal-title":"PLoS ONE"},{"key":"385_CR27","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1093\/neuonc\/noz069","volume":"21","author":"SA Upadhyaya","year":"2019","unstructured":"Upadhyaya SA, Robinson GW, Onar-Thomas A et al (2019) Molecular grouping and outcomes of young children with newly diagnosed ependymoma treated on the multi-institutional SJYC07 trial. Neuro Oncol 21:1319\u20131330","journal-title":"Neuro Oncol"},{"key":"385_CR28","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00401-016-1608-3","volume":"132","author":"M Gessi","year":"2016","unstructured":"Gessi M, Capper D, Sahm F et al (2016) Evidence of H3 K27M mutations in posterior fossa ependymomas. Acta Neuropathol 132:635\u2013637","journal-title":"Acta Neuropathol"},{"key":"385_CR29","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s00381-017-3481-3","volume":"33","author":"S Ryall","year":"2017","unstructured":"Ryall S, Guzman M, Elbabaa SK et al (2017) H3 K27M mutations are extremely rare in posterior fossa group A ependymoma. Childs Nerv Syst 33:1047\u20131051","journal-title":"Childs Nerv Syst"},{"key":"385_CR30","doi-asserted-by":"publisher","first-page":"a026443","DOI":"10.1101\/cshperspect.a026443","volume":"7","author":"DN Weinberg","year":"2017","unstructured":"Weinberg DN, Allis CD, Lu C (2017) Oncogenic mechanisms of histone H3 mutations. Cold Spring Harb Perspect Med 7:a026443","journal-title":"Cold Spring Harb Perspect Med"},{"key":"385_CR31","doi-asserted-by":"publisher","first-page":"36530","DOI":"10.18632\/oncotarget.26370","volume":"9","author":"HA Rogers","year":"2018","unstructured":"Rogers HA, Chapman R, Kings H et al (2018) Limitations of current in vitro models for testing the clinical potential of epigenetic inhibitors for treatment of pediatric ependymoma. Oncotarget 9:36530\u201336541","journal-title":"Oncotarget"},{"key":"385_CR32","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/cncr.29198","volume":"121","author":"AM Li","year":"2015","unstructured":"Li AM, Dunham C, Tabori U et al (2015) EZH2 expression is a prognostic factor in childhood intracranial ependymoma: a Canadian Pediatric Brain Tumor Consortium study. Cancer 121:1499\u20131507","journal-title":"Cancer"},{"key":"385_CR33","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/bpa.12042","volume":"23","author":"S Venneti","year":"2013","unstructured":"Venneti S, Garimella MT, Sullivan LM et al (2013) Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas. Brain Pathol 23:558\u2013564","journal-title":"Brain Pathol"}],"updated-by":[{"DOI":"10.1007\/s10014-020-00393-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T00:00:00Z","timestamp":1610150400000}}],"container-title":["Brain Tumor Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10014-020-00385-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10014-020-00385-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10014-020-00385-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T02:10:38Z","timestamp":1611022238000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10014-020-00385-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["385"],"URL":"https:\/\/doi.org\/10.1007\/s10014-020-00385-9","relation":{},"ISSN":["1433-7398","1861-387X"],"issn-type":[{"value":"1433-7398","type":"print"},{"value":"1861-387X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,1]]},"assertion":[{"value":"28 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the original publication of the article, the middle name was missing in corresponding author\u2019s name.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}